Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This drug is a combination vaccine (DTaP-IPV) designed to provide active immunization against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. It contains toxoids of diphtheria and tetanus, acellular components of *Bordetella pertussis* (typically pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus types 1, 2, and 3 (Mahoney, MEF-1, and Saukett strains). The vaccine works by inducing the production of specific antibodies against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, the antigens of *Bordetella pertussis*, and the three types of poliovirus, thereby providing protection against the respective diseases. It is primarily used for primary vaccination in infants and as a booster dose in young children and pregnant women.
- Brand names
- TetravacInfanrix-IPVKinrixQuadracel
- Other names
- DTaP-IPV4-in-1 vaccineneloisrokotediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine
02
Targets
FIM2/FIM3 (Fimbriae types 2 and 3)FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed).